Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Deferred Taxes (2016 - 2018)

Historic Deferred Taxes for Spero Therapeutics (SPRO) over the last 3 years, with Q4 2018 value amounting to $645000.0.

  • Spero Therapeutics' Deferred Taxes rose 205454.55% to $645000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $554000.0, marking a year-over-year increase of 53281.25%. This contributed to the annual value of $554000.0 for FY2018, which is 53281.25% up from last year.
  • Per Spero Therapeutics' latest filing, its Deferred Taxes stood at $645000.0 for Q4 2018, which was up 205454.55% from -$32000.0 recorded in Q3 2018.
  • In the past 5 years, Spero Therapeutics' Deferred Taxes registered a high of $645000.0 during Q4 2018, and its lowest value of -$497000.0 during Q1 2017.
  • For the 3-year period, Spero Therapeutics' Deferred Taxes averaged around $44222.2, with its median value being -$32000.0 (2018).
  • Examining YoY changes over the last 5 years, Spero Therapeutics' Deferred Taxes showed a top increase of 205454.55% in 2018 and a maximum decrease of 10528.74% in 2018.
  • Quarter analysis of 3 years shows Spero Therapeutics' Deferred Taxes stood at -$28000.0 in 2016, then decreased by 17.86% to -$33000.0 in 2017, then skyrocketed by 2054.55% to $645000.0 in 2018.
  • Its Deferred Taxes stands at $645000.0 for Q4 2018, versus -$32000.0 for Q3 2018 and -$23000.0 for Q2 2018.